Safety and Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine Booster in Taiwanese Toddlers  by Shao, Pei-Lan et al.
542 J Formos Med Assoc | 2006 • Vol 105 • No 7
ORIGINAL ARTICLE
Streptococcus pneumoniae (pneumococcus) is an
important cause of mucosal infections (otitis
media, sinusitis, pneumonia) and invasive infec-
tions (bacteremia, meningitis) worldwide.1 Mor-
bidity and mortality due to pneumococcal
infection remain high in pediatric groups, espe-
cially in children younger than 2 years old.2,3
Estimated incidences of invasive pneumococcal
infections among children aged < 12 months and
12–23 months in the United States were 165 and
203 cases/100,000 population, respectively.4 Emer-
gence of multidrug-resistant pneumococci and
the high carriage rate of penicillin-nonsusceptible
S. pneumoniae among children are critical concerns
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(for serotype 18C) to 100% (for serotype 14) of subjects had antibody concentrations ≥ 0.2 μg/mL to 
 different pneumococcal serotypes. After the booster dose, the geometric mean concentration of IgG
increased significantly (p < 0.001) for all seven serotypes indicating the induction of immunologic mem-
ories. Ninety-eight percent of the toddlers had antibody concentration ≥ 0.2 μg/mL against all serotypes
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in recent decades.5 Therefore, successful preven-
tion of pneumococcal infections by effective vac-
cination is an urgent need.
The heptavalent pneumococcal conjugate 
vaccine (PrevenarTM, Wyeth, Madison, NJ, USA)
(7VPnC), in which pneumococcal capsular poly-
saccharides are covalently linked to a carrier 
protein, CRM197, has been demonstrated to be
immunogenic in Taiwanese infants after admini-
stration of three consecutive doses.1 More than
95% of Taiwanese infants acquired an antibody
concentration ≥ 0.2 μg/mL to all seven serotypes
after three doses of vaccine.1 The 7VPnC vaccine
has shown excellent efficacy of 97% against inva-
sive pneumococcal diseases caused by the vac-
cine serotypes.6 The serotype-specific efficacy for
acute otitis media (AOM) in the Finnish Otitis
Media Vaccine Trial was 57%.7 Furthermore, the
conjugate vaccine is able to induce immunologic
memory and produce a significant rise in anti-
body titers after a booster dose.6,8–10 However,
maintenance of antibody concentration up to the
booster age is important for protection against
pneumococcal diseases in late infancy and in todd-
lers. In this study, we investigated the antibody
concentrations before the scheduled booster dose
and evaluated the safety and immunogenicity
after administration of a booster dose of the
7VPnC vaccine in Taiwanese toddlers.
Methods
Subjects
Fifty-eight out of 60 healthy toddlers who previ-
ously received the three-dose primary series of
7VPnC vaccine (PrevenarTM) were enrolled in
this trial at National Taiwan University Hospital
from June to September 2002. The primary series of
heptavalent pneumococcal conjugate vaccine had
been administrated at 2, 4, and 6 months of age
(± 2 weeks) with a minimum of 3 weeks between
each dose.1 Subjects with the following conditions
were excluded: (1) hypersensitivity to any com-
ponent of the study vaccine, including diphthe-
ria toxoid; (2) known or suspected impairment
of immunologic functions or receiving immuno-
suppressive therapy; (3) anaphylactic reactions to
prior doses of study vaccine; (4) a history of pre-
vious invasive pneumococcal infection; and (5)
received gamma globulin in the past 3 months.
The protocol of the study was approved by the in-
stitutional review board of the hospital. Written
rinformed consent was obtained from parents o
legal guardians of each child before enrollment.
Vaccines and immunizations
The heptavalent pneumococcal conjugate vaccine
(PrevenarTM) (0.5 mL) contained 2 μg of serotypes
4, 9V, 14, 19F, and 23F polysaccharides; 2 μ fg o
serotype 18C oligosaccharide; 4 μg of serotype 6B
polysaccharide; 20 μg of cross-reacting molecule
197 (CRM197); and 0.125mg of aluminum phos-
phate per dose. The study vaccine was administered
at the age of 15–20 months in an open-labeled,
noncomparative manner. The vaccine was ad-
ministered intramuscularly into the rleft anterio
lateral thigh. Routine vaccines including rbooste
rdoses of either diphtheria–tetanus toxoid-acellula
pertussis (DTaP) vaccine or diphtheria–tetanus
toxoid-whole cell pertussis (DTwP) vaccine, and
oral polio vaccine (OPV) were administered con-
comitantly with the study vaccine.
Safety surveillance
The parents or guardians of each child were
given a diary card and a digital thermometer and
asked to record rectal temperatures and local and
systemic reactions for 14 days after vaccination.
Local reactions examined at the injection sites
included the following: (1) the presence or ab-
sence of redness or swelling, and its size if pres-
ent; and (2) the presence or absence of tenderness,
and whether it interfered with movement of the
legs. The presence of systemic reactions was
assessed by measuring the highest daily rectal
r temperature, sleep patterns, the presence o
fabsence of abnormal fussiness, irritability, loss o
appetite, vomiting, diarrhea, rashes, and change
in skin color. Telephone interviews with parents/
guardians were conducted at 48 hours and 14 days
gafter vaccination to collect information regardin
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local and systemic reactions. Further adverse event
data were collected for 1 month after the immu-
nization visit. All events were classified according
to severity, recovery, and in relation to the study
vaccine.
Immunogenicity evaluation
Serum specimens were obtained just before the
booster dose of the study vaccine was adminis-
tered and 1 month after. Specimens were labeled
and sent to Wyeth Lederle Laboratories (West
Henriette, NY, USA) for blinded analysis. Stan-
dard enzyme-linked immunosorbent assay (ELISA)
was used to quantify serum immunoglobulin G
(IgG) to each of the seven serotypes contained in
the study vaccine.11 ELISA units were converted 
to μg/mL of IgG by using a standard reference
serum 89SF.
Statistical analysis
Frequency and proportion were used to sum-
marize the categorical variables and safety para-
meters. For the immunologic studies, geometric
mean concentration (GMC) and 95% confidence
intervals were determined for antibodies to each
pneumococcal vaccine serotype. Paired t test was
used to compare the GMC difference between pre-
booster dose and post-booster dose of the study
vaccine to each serotype. The proportion of tod-
dlers at or above the defined antibody titer of 
≥ 0.2 μg/mL for each of the seven serotypes was
calculated and compared by Fisher’s exact test.
Results
Subjects
Fifty-eight healthy toddlers (27 male and 31
female) aged 17–19 months (mean age, 17.79
months) were enrolled in the study (Table 1). All
of the enrolled toddlers were Taiwanese, except for
one Caucasian. All of the 58 subjects had com-
pleted the primary series of 7VPnC vaccine, DTaP
or DTwP, and OPV immunization. All subjects
had completed hepatitis B vaccination except for
one subject, who missed the second dose of the
vaccine. Prior vaccinations which had been recei-
ved by the enrolled subjects are listed in Table 1.
None of the toddlers developed breakthrough
invasive pneumococcal disease after the three-
dose primary series of the 7VPnC vaccine. The
rvaccines given concurrently with the booste
dose of the study vaccine were as follows: DTwP
vaccine and OPV were concurrently adminis-
V tered in 49 subjects, DTaP vaccine and OP
in three, MMR vaccine in four, and Japanese
encephalitis vaccine in one. Fifty-six toddlers
completed the study protocol. Two finished the
safety surveillance, but did not have serum
collected for measurement of antibodies.
Safety
Local reactions
tThe most frequently reported local reaction a
the study vaccine injection site (left thigh) was
redness (50%), followed by swelling (47%) and
tenderness (45%) (Table 2). The sizes of the red
or swelling areas were usually less than 2 cm.
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Table 1. Demographic and other baseline
characteristics of subjects (n = 58)
Gender
Male 27 (47%)
Female 31 (53%)
Age (mo)
Mean (range) 17.79 (17–19)
Race
Asian 57 (98%)
Caucasian 1 (2%)
Prior vaccinations
BCG 58 (100%)
HBV 58 (100%)*
DTwP/DTaP 58 (100%)†
OPV 58 (100%)†
Hib 6 (10%)*
JEV 14 (24%)*
MMR 17 (29%)*
PrevenarTM 58 (100%)†
*Subjects who had received at least one dose of vaccine; †subjects
who had received three-dose primary series of the vaccines. BCG =
Bacillus Calmette-Guérin; HBV = hepatitis B vaccine; OPV = oral
polio vaccine; Hib = Haemophilus influenzae type b vaccine; JEV =
Japanese encephalitis vaccine; MMR=measles, mumps and rubella
vaccine.
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There were four (7%) toddlers who experienced
pain that interfered with leg movement. All local 
reactions resolved within 48 hours postvaccination.
Systemic reactions
Commonly encountered systemic reactions 
included the following: fever (50%), fussiness
(41%), restlessness (38%), and loss of appetite
(31%) (Table 2). Fever onset (mostly with rectal
temperature between 38° C and 39° C) generally 
occurred within 12 hours, usually lasted for 12
hours, and subsided within 72 hours in all cases.
Sixty-two percent of subjects who developed
fever had taken antipyretics after fever onset. All
systemic reactions resolved by the time of the 
14-day telephone interview.
Adverse events
Eleven adverse events from seven (12%) subjects
were noted in this study (Table 3). These events
consisted of skin rash (n = 5), skin candidiasis
(n = 1), gastroenteritis (n = 1), dyspepsia (n = 1),
fecal impaction (n = 1), respiratory tract infection
(n = 1), and balanitis (n = 1). One toddler had
two vaccine-related adverse events, rash and dys-
pepsia. Both of these adverse events were mild
and resolved spontaneously without medication.
tThere were no serious adverse events. No subjec
withdrew from the study due to adverse events.
Immunogenicity
tThe prebooster GMC of the antibodies agains
pneumococcal polysacchrides ranged from 0.31
μg/mL (for serotype 18C) to 1.63 μg/mL (for sero-
type 14). The study vaccine had elicited a signifi-
cant immunologic response to all seven vaccine
serotypes. After the booster dose of vaccine, the
GMC of antibodies showed a significant increase
against all seven pneumococcal serotypes (p <
0.001) (Table 4). There was a marked difference
in the response to individual serotypes. The post-
booster antibody GMCs ranged from 4.22 to
24.03 μg/mL, with the lowest against serotype
18C and the highest against serotype 6B (Figure
1). The GMCs showed 9- to 23-fold increases,
Table 2. Incidence of local reactions (within 48
hours) or systemic reactions (within 14
days) after booster dose vaccination
Reaction n = 58
Local redness
< 2 cm 19 (33%)
2–4 cm 8 (14%)
> 4 cm 2 (3%)
Total 29 (50%)
Local swelling
< 2 cm 19 (33%)
2–4 cm 7 (12%)
> 4 cm 1 (2%)
Total 27 (47%)
Local pain 26 (45%)
Interference with leg movement 4 (7%)
Fever (≥ 38.0°C) 29 (50%)
Fussiness 24 (41%)
Restlessness 22 (38%)
Loss of appetite 18 (31%)
Lethargy 10 (17%)
Vomiting 8 (14%)
Diarrhea 7 (12%)
Rash 7 (12%)
Change in skin color 1 (2%)
Table 3. Incidence of adverse events (AEs) after
booster dose vaccination
n = 58
All subjects with AEs* 7 (12%)
Digestive system
Gastroenteritisa 1 (2%)
Dyspepsiab 1 (2%)
Fecal impactionc 1 (2%)
Respiratory system
Infectiond 1 (2%)
Skin and appendages
Candidiasisd 1 (2%)
Rashbdef 5 (9%)
Urogenital system
Balanitisg 1 (2%)
Subject with vaccine-related AEsb 1 (2%)
Serious AEs 0 (0%)
Withdrew due to AEs 0 (0%)
*Eleven AEs reported from seven subjects; abcdefgindicate specific
subjects who developed AEs.
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depending on serotypes, from prebooster to post-
booster dose of vaccination. The proportion of
toddlers with antibody concentrations ≥0.2μg/mL
before the booster dose ranged from 68% for
serotype 18C to 100% for serotype 14 (Table 5)
(Figure 2). After the booster dose, 98% of tod-
dlers acquired antibody concentrations ≥ 0.2
μg/mL to all seven serotypes. The percentage of
toddlers with antibody concentrations ≥ 1 μg/mL
rafter the booster dose ranged from 95% fo
serotype 23F to 100% for serotype 14 and 19F.
Discussion
This study has demonstrated that a booster dose
of heptavalent pneumococcal conjugate vaccine
containing serotypes 4, 6B, 9V, 14, 18C, 19F and
 23F can be safely administered to Taiwanese
toddlers at the age of 15 to 20 months. Local re-
actions (redness, swelling, tenderness) at the injec-
tion site were common and ranged from 45% to
g50%. Compared with the incidences noted durin
the primary immunization series in these subjects
(17–30%),1 the local reaction rates were signifi-
cantly higher after the booster dose for local red-
ness and local swelling (p < 0.0001), and for local
pain (p = 0.0154). Fever was the most common
fsystemic reaction and was observed in 50% o
toddlers, which is a higher rate than was reported
in the United States,6,8,9 but is comparable to a
primary series study in Taiwanese infants.1
rThe 7VPnC vaccine elicited a significant booste
immunologic response to all seven serotypes in the
gpreviously primed subjects (Figure 1), indicatin
ythe induction of immunologic memory. The stud
vaccine is more immunogenic in Taiwanese tod-
dlers than in toddlers of developed countries. The
postbooster GMCs found in this study, which
ranged from 4.22 to 24.03 μg/mL, are much
higher than those reported in the United States,
Table 4. Geometric mean concentrations of pneumococcal antibodies in recipients of the heptavalent pneumococcal
conjugate vaccine
Geometric mean concentrations (μg/mL)
Serotype
Prebooster (95% CI) Postbooster (95% CI) Mean fold rise
p
4 0.44 (0.35–0.55) 6.28 (4.85–8.14) 14.27 < 0.001
6B 1.03 (0.75–1.41) 24.03 (17.86–32.35) 23.33 < 0.001
9V 0.47 (0.37–0.60) 4.62 (3.77–5.66) 9.83 < 0.001
14 1.63 (1.24–2.15) 16.42 (12.54–21.50) 10.07 < 0.001
18C 0.31 (0.25–0.37) 4.22 (3.35–5.31) 16.00 < 0.001
19F 0.54 (0.41–0.71) 8.64 (7.05–10.58) 13.61 < 0.001
23F 0.53 (0.37–0.74) 12.12 (8.83–16.64) 22.87 < 0.001
CI = confidence interval.
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Finland and Germany, which ranged from 1.76 to
12.27 μg/mL.6–9,12 The GMCs also showed greater
increases from prebooster to postbooster dose
in this study than in previous reports.8,9 A 9-
(serotype 9V) to 23-fold (serotype 6B) increase
was noted in this study, compared with a 5- to
15-fold rise in previous reports.8,9
The antibody concentration required to pro-
tect against pneumococcal diseases is of great in-
terest, but remains to be well established. On the
basis of vaccine efficacy trial data, Jodar et al10
proposed that a serotype nonspecific threshold
antibody concentration of ≥ 0.2 μg/mL predicted
protection against invasive pneumococcal dis-
eases. The decline of the age-specific invasive dis-
 ease rates was also well correlated with the
yincrease in proportions of infants with antibod
concentration above this threshold (≥ 0.2 μg/
mL).10 In our study, 55 of the 56 toddlers (98%)
gained the antibody concentration of ≥ 0.2 μg/
mL to all serotypes after the booster dose (Table 4).
rHigher antibody concentrations are required fo
prevention of AOM than to prevent invasive dis-
eases.13 yThe protective levels for AOM also var
greatly among serotypes. An otitis media vaccine
trial in Finland showed that serotype 6B was
Table 5. Numbers of vaccines with antibody concentrations above suggested protective level
Number of infants with antibody Number of toddlers with antibody
Serotype concentrations ≥ 0.2 μg/mL (n = 60) concentrations ≥ 0.2 μg/mL (n = 56)
Prevaccination Postdose 3 p Prebooster Postbooster p
4 11 (18%) 60 (100%) < 0.0001 45 (80%) 56 (100%) 0.0001
6B 25 (42%) 58 (97%) < 0.0001 52 (93%) 55 (98%) 0.1138
9V 26 (43%) 60 (100%) < 0.0001 49 (88%) 56 (100%) 0.0028
14 46 (77%) 60 (100%) < 0.0001 56 (100%) 56 (100%) N/A
18C 15 (25%) 60 (100%) < 0.0001 38 (68%) 56 (100%) < 0.0001
19F 37 (62%) 60 (100%) < 0.0001 51 (91%) 56 (100%) 0.0073
23F 18 (30%) 57 (95%) < 0.0001 43 (77%) 56 (100%) < 0.0001
N/A = not applicable.
iF gure 2. l d b f ( ) b d ( ) b b dReverse cumu ative istri ution curves o  A  pre ooster an  B  post ooster anti o y concentrations.
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highly efficacious (>65%) at a GMC of 0.5 μg/
mL. In contrast, the efficacy of serotype 19F was
lower and did not increase with the antibody
concentration.13
Antibody concentrations may gradually dimin-
ish after a primary series of doses and may or may
not fall below the estimated protective threshold.
However, the highest invasive pneumococcal dis-
ease risk occurs between the third and the booster
dose.4 Therefore, the optimal timing of the booster
dose depends on whether the antibody concentra-
tion can be maintained above the protective level
until the prebooster age. In this study, the propor-
tions of toddlers with antibody concentration of 
≥0.2μg/mL before the booster dose were between
88% and 100% for serotypes 6B, 9V, 14 and 19F
(Table 5). In contrast, only 68% retained this anti-
body concentration against serotype 18C at the age
of 15–20 months. In order to maintain an adequate
antibody concentration at the age with the highest
disease risk, advancing the time of administration
of the booster dose may be considered.
Conjugate vaccines are T-cell-dependent anti-
gens and are able to induce immunologic mem-
ory.14 A study of Haemophilis influenzae type b
(Hib) conjugate vaccine revealed that elevated
antibody concentrations persisted for at least 8
years after vaccination in early infancy and were
maintained through anamnestic responses to re-
peated natural exposure to Hib or cross-reacting
bacteria.15 Therefore, it is reasonable to predict
that induction of immunologic memory will be
sufficient for long-term protection against disease.10
Since the heptavalent pneumococcal conjugate
vaccine (PrevenarTM) used in this study was li-
censed in 2000 in the United States, routine use of
the vaccine has been associated with a substantial
reduction in the invasive disease rate in chil-
dren.16–18 In addition to invasive diseases, conju-
gate vaccines also protect against asymptomatic
carriage and, therefore, result in herd immunity for
unvaccinated populations.17,19 However, critical
concern about serotype replacement emerged after
the use of pneumococcal conjugate vaccine. It was
reported that the rate of invasive pneumococcal
diseases due to nonvaccine serotypes increased
rfrom 1.8 cases per 100,000 in 1999 to 2.8 cases pe
100,000 in 2002 among persons aged 2 years and
older.18 In children with recurrent AOM, immedi-
ate and complete replacement by nonvaccine
pneumococcal serotypes took place in naso-
pharyngeal colonization after vaccination.20
Furthermore, transformation of pneumococcal
polysaccharide capsule was found in vaccine-
related serotypes.21 The occurrences of serotype
yreplacement and capsular transformation ma
taffect the long-term efficacy of the heptavalen
pneumococcal conjugate vaccine. Pneumococcal
serotypes reported to be prevalent in Taiwan in-
cluded 23F, 19F, 6B, 14, 9 and 3.5,22,23 rWhethe
or not the emergence of nonvaccine-related sero-
types, especially serotype 3, would occur after intro-
ducing the 7VPnC vaccine in Taiwan remains
unclear.
In conclusion, the heptavalent pneumococcal
conjugate vaccine booster is safe and immuno-
genic in Taiwanese toddlers. Administration of the
booster dose resulted in a significant rise in anti-
fbody concentration indicating the induction o
immunologic memories. The booster dose seems
to be more immunogenic in Taiwanese than in
American and European toddlers. Due to the preva-
lence of vaccine-related serotypes in Taiwan,1,5,22,23
introduction and administration of the conju-
gate vaccine will prevent substantial pneumococ-
cal diseases in Taiwan.
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